Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues

DNA and Cell Biology

Volumn 32, Issue 1, 2013, Pages 13-18

  Daǧlar Aday, Aynur ^a   Toptaş, Bahar ^a   Öztürk, Tülin ^b   Seyhan, Fatih ^a   Saygili, Neslihan ^a   Eronat, Allison Pinar ^a   Akadam Teker, Başak ^a   Yilmaz Aydoǧan, Hülya ^a   Aksoy, Figen ^b   Öztürk, Oǧuz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID HYPERPLASIA; TUMOR GROWTH; TUMOR VOLUME; TURKEY (REPUBLIC);

ADULT; AGED; AMINO ACID SUBSTITUTION; CARCINOMA, PAPILLARY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SEX FACTORS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84873050138     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1776     Document Type: Article

References (40)

1. Adeniran, A.J., Zhu, Z., Gandhi, M., Steward, D.L., Fidler, J.P., Giordano, T.J., Biddinger, P.W., and Nikiforov, Y.E. (2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30, 216-222
2. Avruch, J., Khokhlatchev, A., Kyriakis, J.M., Luo, Z., Tzivion, G., Vavvas, D., and Zhang, X.F. (2001). Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56, 127-155
3. Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W.H., Ladenson, P.W., and Sidransky, D. (2003). BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95, 625-627
4. Correa, P., and Chen, V.W. (1995). Endocrine gland cancer. Cancer 75, 338-352
5. Daum, G., Eisenmann-Tappe, I., Fries, H.W., Troppmair, J., and Rapp, U.R. (1994). The ins and outs of Raf kinases. Trends Biochem Sci 19, 474-480
6. Davies, L., and Welch, H.G. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167
7. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al.(2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954
8. DeLelis, R., Lloyd, R., Heitz, Ph., Eng, Ch., eds. (2004). WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs (IARC Press, Lyon) p. 320
9. Dohan, O., Baloch, Z., Banrevi, Z., Livolsi, V., and Carrasco, N. (2001). Rapid communication: Predominant intracellular overexpression of the Na (+) /I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86, 2697-2700
10. Duesbery, N.S., Webb, C.P., and Vande Woude, G.F. (1999 MEK wars, a new front in the battle against cancer. Nat Med 5, 736-737
11. Ezzat, S., Zheng, L., Kolenda, J., Safarian, A., Freeman, J.L., and Asa, S.L. (1996). Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6, 409-416
12. Franco, A.T., Malaguarnera, R., Refetoff, S., Liao, X.-H., Lundsmith, E., Kimura, S., Pritchard, C., Marais, R., Davies, T.F., Weinstein, L.S., et al.(2011). Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A 108, 1615-1620
13. Frasca, F., Nucera, C., Belfiore, A., Piero, G., Attard, M., Stella, M., Pellegriti, G., Giordano, C., Trimarchi, F., and Vigneri, R. (2006). BRAF T1799A mutation in thyroid cancer predicts progressive disease. Program of the 88th Annual Meeting of The Endocrine Society, June 24-27, 2006, Boston, MA (Abstract OR 20-22
14. Fugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V., Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., et al.(2006). Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13, 455-464
15. Garnett, M.J., and Marais, R. (2004). Guilty as charged: BRAF is a human oncogene. Cancer Cell 6, 313-319
16. Hundahl, S.A., Fleming, I.D., Fremgen, A.M., and Menck, H.R. (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83, 2638-2648
17. Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O.H., Duh, Q.Y., Shibru, D., Bastian, B., and Griffin, A. (2007). The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246, 466-471
18. Kim, J., Giuliano, A.E., Turner, R.R., Gaffney, R.E., Umetani, N., Kitago, M., Elashoff, D., and Hoon, D.S. (2006). Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 244, 799-804
19. Kim, K.H., Suh, K.S., Kang, D.W., and Kang, D.Y. (2005 Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 55, 540-545
20. Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E., and Fagin, J.A. (2003). High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63, 1454-1457
21. Kroll, T.G., Sarraf, P., Pecciarini, L., Chen, C.J., Mueller, E., Spiegelman, B.M., and Fletcher, J.A. (2000). Pax8-PPAR gamma1 fusion oncogene in human thyroid carcinoma. Science 289, 1357-1360
22. Kumar, R., Angelini, S., Snellman, E., and Hemminki, K. (2004 BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122, 342-348
23. Kurtulmus, N., Duren, M., Ince, U., Yakicier, M.C., Peker, O., Aydin, O., Altiok, E., Giray, S., and Azizlerli, H. (2012 BRAFV600E mutation in Turkish patients with papillary thyroid cancer: Strong correlation with indicators of tumor aggressiveness. Endocrine 42, 404-410
24. Liu, R.T., Chen, Y.J., Chou, F.F., Wu, W.L., Tsai, P.C., Huang, C.C., and Cheng, J.T. (2005). No correlation between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol 63, 461-466
25. Namba, H., Rubin, S.A., and Fagin, J.A. (1990). Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4, 1474-1479
26. Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T.I., Ohtsuru, A., Saenko, V.A., Kanematsu, T., and Yamashita, S. (2003). Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88, 4393-4397
27. Nikiforov, Y.E. (2002). RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13, 3-16
28. Nikiforova, M.N., Kimura, E.T., Gandhi, M., Biddinger, P.W., Knauf, J.A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al.(2003). BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88, 5399-5404
29. Peyssonnaux, C., and Eychene, A. (2001). The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell 93, 53-62
30. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., and Rosen, N. (2009). (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 106, 4519-4524
31. Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E.D., Fadda, G., et al.(2004). BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89, 2414-2420
32. Santoro, M., Papotti, M., Chiappetta, G., Garcia-Rostan, G., Volante, M., Johnson, C., Camp, R.L., Pentimalli, F., Monaco, C., Herrero, A., et al.(2002). RET activation and and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87, 370-379
33. Sapio, M.R., Posca, D., Troncone, G., Pettinato, G., Palombini, L., Rossi, G., Fenzi, G., and Vitale, M. (2006). Detection of BRAF mutation in thyroid papillary carcinomas by mutant allelespecific PCR amplification (MASA). Eur J Endocrinol 154, 341-348
34. Smith, R.A., Salajegheh, A., Weinstein, S., Nassiri, M., and Lam, A.K. (2011). Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 42, 500-506
35. Tang, K.T., and Lee, C.H. (2010). BRAF mutation in papillary thyroid carcinoma: Pathogenic role and clinical implications. J Chin Med Assoc 73, 113-128
36. TurkStat, Turkey in Statistics. (2011). Available at www.turkstat .gov.tr/mvg-inter (last accessed June 9, 2012
37. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., et al.(2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867
38. Xing, M. (2005). BRAF mutation in thyroid cancer. Endocr Relat Cancer 12, 245-262
39. Xing, M., Westra, W., Tufano, R.P., Cohen, Y., Rosenbaum, E., Thoden, K.J., Carson, K.A., Vasko, V., Larin, A., Tallini, G., et al.(2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90, 6373-6379
40. Xing, M. (2007). BRAF mutation in papillary thyroid cancer pathogenic role, molecular bases, and clinical implications. Endocrine Rev 28, 742-776.